SEC
CFPB Strips ECOA Disparate Impact, July 21
The CFPB's April 2026 ECOA rule kills disparate impact for credit cards and auto loans, but leaves mortgage lenders still exposed under the FHA.
Latest — Page 37
Legal
Passed: Virginia SB229 Adds Class Actions to State Courts
Virginia's class action bill looks like a consumer win, until you see where the $424 million goes. Mississippi would then stand alone.
Legal
FEMITBOT Spoofs Apple, NVIDIA in Telegram Fraud Ring
A Telegram fraud ring called FEMITBOT is spoofing Apple, NVIDIA, and six other major brands to harvest deposits from fake crypto dashboards.
FDA
Supreme Court Restores Mifepristone Mail Access
Mail-order mifepristone is back after the Supreme Court reversed an appeals stay, but the litigation that created the disruption is still running.
Deals
Amgen Adds $300M to Puerto Rico Biologics Site
Amgen drops another $300M into its Puerto Rico biologics site, bringing Juncos to nearly $1B total and U.S. manufacturing pledges close to $2B.
Deals
Bid $55.5B for eBay: GameStop Can't Cover It
GameStop offered $55.5B for eBay at $125 a share, a 46% premium, but CNBC's math found a $16 billion gap Ryan Cohen couldn't explain.
FDA
ODAC Rejects AstraZeneca Camizestrant 6-3 After 9 Months
FDA ended nine adcomm-free months on April 30 with split votes on two AstraZeneca cancer drugs, but consultants warn it's a narrow restart.
Legal
ShinyHunters Steals 275M Instructure Canvas Records
ShinyHunters claims 275 million student and teacher records stolen from Instructure's Canvas platform, hitting nearly 9,000 schools worldwide.
Deals
Windward Bio Raises $165M for Late-Stage Trial
Swiss biotech Windward Bio raised $165M to advance a China-derived drug into late-stage testing. What investors get from this bet is the real question.
Deals
Ken Song's T Cell Engager Bet Gets Picked Up
Ken Song has done it again.
FDA
FDA Clears Pfizer-Arvinas Veppanu as First PROTAC
FDA cleared Veppanu on Friday as the first-ever PROTAC therapy, a new drug class that actively degrades disease-causing proteins rather than just blocking them.
Deals
Bought Candid for $2B, UCB Challenges Gilead on TCE
UCB bought Candid Therapeutics for $2 billion upfront, plus up to $200 million in development milestones, cutting off a planned reverse merger with…
FDA
Celcuity Beats Piqray in Phase 3, Shares Jump 15%
Pfizer sold gedatolisib to Celcuity for $10 million upfront in 2021.
Legal
Defender Pulls DigiCert Root Certs in False-Positive Hit
Microsoft's Defender antivirus flagged legitimate DigiCert root certificates as Trojan:Win32/Cerdigent.
Legal
Instructure Hit by Second Breach in Eight Months
A criminal threat actor hit Instructure, the company behind the Canvas learning management system, in a cyberattack disclosed this week.
